Antibody therapeutics remain central to modern biomedicine, with major applications across oncology, autoimmune diseases, metabolic diseases, infectious diseases, and chronic inflammatory disorders. Successful therapeutic antibody development requires more than antigen binding alone: discovery teams need diverse antibody repertoires, robust immune responses, functional screening, cross-species assessment, developability analysis, and translational validation.
Cyagen’s HUGO-Mab™ platform is designed to support this workflow from the earliest stage of antigen design and immunization through antibody sequence acquisition, recombinant expression, binding and blocking validation, affinity measurement, epitope analysis, and in vitro or in vivo pharmacology studies. The platform can be integrated with hybridoma screening, droplet microfluidics-based single B-cell screening, Beacon® single-cell optofluidic screening, AbSeek™ computational analysis, and Cyagen’s broader model and CRO validation capabilities.
HUGO-Mab™ mice are designed to generate human variable-region monoclonal antibody candidates directly through in vivo immunization. By replacing mouse immunoglobulin variable-region loci with human sequences, the platform enables discovery of antibodies with human VH/Vκ/Vλ repertoires while preserving the biological context of antigen-driven B-cell activation and maturation.
The schematic below illustrates the chain-specific humanization design of HUGO-Ab™ mouse models, showing how human immunoglobulin variable regions are incorporated across heavy-chain, κ light-chain, and λ light-chain loci to support fully human antibody generation in vivo.
- Developed using Cyagen's proprietary TurboKnockout gene editing technology for precise genomic replacement
- Complete substitution of mouse heavy and light chain variable genes with human sequences,ensuring fully human antibodies
- Retention of natural antibody effector functions (e.g., ADCC and CDC), facilitating biologically active antibody production
- Robust immunogenicity, delivering high-affinity antibody molecules and streamlining therapeutic antibody development
- {{v2}}
- {{item}}
- {{v2}}
- {{item}}
High-Homology Target: HUGO-Mab-eKO™ Accelerates ACVR2A Antibody Development
ACVR2A is a type II transmembrane receptor in the TGF-β superfamily and a promising therapeutic target for muscle atrophy, sarcopenia, obesity, fatty liver disease, and related metabolic disorders. However, the high sequence similarity between human and mouse ACVR2A creates a significant immune-tolerance barrier in wild-type mice, making conventional antibody generation highly challenging.
- {{v2}}
- {{item}}
